Ryvu Therapeutics Discovers Synergistic mTOR-AKT Inhibitor Combination for Colorectal Cancer Treatment
核心洞察
Ryvu Therapeutics (搜索) published research in Scientific Reports revealing synergistic effects between mTOR (搜索) inhibitor everolimus and AKT (搜索) inhibitor uprosertib in colorectal cancer (搜索) cells.
The study utilized patient-derived primary cell cultures and high-throughput screening of over 4,200 compounds, identifying 33 compounds with selective activity against cancer cells.
The ONCO Prime platform integrates artificial intelligence to enhance drug discovery precision and has already identified several undisclosed novel targets for colorectal cancer (搜索) treatment.
Ryvu Therapeutics (搜索) has published breakthrough research in Scientific Reports demonstrating a promising synergistic drug combination for colorectal cancer (搜索) treatment. The study reveals that combining mTOR (搜索) and AKT (搜索) inhibitors produces significant therapeutic synergy, potentially offering a new treatment strategy for patients with this challenging malignancy.
Novel Drug Discovery Platform Yields Promising Results
The research stems from Ryvu's proprietary ONCO Prime target discovery platform, which conducted high-throughput screening of 4,255 compounds using patient-derived primary colorectal cancer (搜索) cell cultures. This approach identified 33 compounds with selective efficacy against cancer cells while sparing normal, healthy epithelial cells.
The standout finding emerged from testing the combination of everolimus, which blocks mTOR (搜索), and uprosertib, which blocks AKT (搜索). These two inhibitors demonstrated significant synergy with a favorable therapeutic window, suggesting improved efficacy compared to single-agent treatments.
"This publication validates our ONCO Prime approach, which combines advanced modelling with AI to identify meaningful therapeutic opportunities," said Krzysztof Brzozka, chief scientific officer at Ryvu. "Our findings underscore the broader potential of the platform."
Patient-Derived Models Offer Translational Advantages
The study's methodology represents a significant advancement over traditional drug discovery approaches. Ryvu's engineered model uses patient-derived cells that reflect the complexity and heterogeneity of primary tumors, characteristics not observed with standard immortalized cell lines.
This translational advantage proved crucial in identifying the mTOR (搜索)-AKT (搜索) synergy. According to the research, this therapeutic combination might have been overlooked using conventional screening methods with immortalized cell lines, reinforcing the value of patient-derived systems for drug discovery.
The patient-derived primary cell cultures serve as models that more closely replicate the complexity and heterogeneity of human tumors than traditional approaches, potentially leading to more clinically relevant discoveries.
AI Integration Enhances Discovery Capabilities
The ONCO Prime platform incorporates artificial intelligence to enhance screening precision and efficiency, enabling scalable discovery of druggable targets across tumor types. The integration of machine learning into the high-throughput screening pipeline significantly improved scalability, cost-efficiency, and predictive accuracy.
This AI-enhanced approach is designed to support the development of more personalized and effective cancer treatments, with the platform expanding beyond colorectal cancer (搜索) to other tumor types.
Expanding Pipeline and Future Prospects
Beyond the published results, the ONCO Prime platform has already led to the discovery of several other novel targets with therapeutic potential in colorectal cancer (搜索). These undisclosed potential targets are currently being advanced through Ryvu's drug discovery process.
The findings underscore the potential of patient-derived materials combined with machine learning-enhanced drug discovery to advance personalized therapies. Specifically, mTOR (搜索)-AKT (搜索) inhibition emerges as a promising strategy for colorectal cancer (搜索) treatment, paving the way for more effective and targeted therapeutic approaches.
The research was published in Scientific Reports, a peer-reviewed, open-access journal that is part of Nature Portfolio and ranks as the 5th most-cited journal in the world, with more than 734,000 citations in 2023.